EU/3/18/2012

Table of contents

About

On 16 April 2018, orphan designation (EU/3/18/2012) was granted by the European Commission to IDEA Innovative Drug European Associates Limited, United Kingdom, for genetically modified replication-incompetent herpes simplex virus-1 expressing collagen VII (also known as KB103) for treatment of epidermolysis bullosa.

Key facts

Active substance
genetically modified replication-incompetent herpes simplex virus-1 expressing collagen VII
Disease / condition
Treatment of epidermolysis bullosa
Date of decision
16/04/2018
Outcome
Positive
Orphan decision number
EU/3/18/2012

Sponsor's contact details

IDEA Innovative Drug European Associates Limited
19 Eastbourne Terrace
London W2 6LG
United Kingdom
Tel. + 44 (0)20 3036 0764
E-mail: info@eurepresentative.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating